CSBio CSBio

X
[{"orgOrder":0,"company":"Jiangsu Atom Bioscience & Pharmaceutical","sponsor":"Xicheng Jinrui Equity Investment Fund","pharmaFlowCategory":"D","amount":"$45.0 million","upfrontCash":"Undisclosed","newsHeadline":"Atom Bioscience Raises $45 Million in Series C Round of Financing to Advance Development of Small Molecule Drugs for Inflammatory and Metabolic Diseases","therapeuticArea":"Rheumatology","highestDevelopmentStatus":"Phase II","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Jiangsu Atom Bioscience & Pharmaceutical"},{"orgOrder":0,"company":"Jiangsu Atom Bioscience & Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Atom Bioscience Announces Positive Phase 2a Results For Investigational New Drug to Treat Chronic Gout","therapeuticArea":"Rheumatology","highestDevelopmentStatus":"Phase II","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Jiangsu Atom Bioscience & Pharmaceutical"},{"orgOrder":0,"company":"OrthoTrophix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TPX-100: OrthoTrophix Presents New Data Suggesting Joint Bone Shape as a Possible Surrogate Marker for Virtual Joint Replacement in Knee Osteoarthritis","therapeuticArea":"Rheumatology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Peptide","productStatus":"New Molecular Entity","date":"April 2022","url1":"","url2":"","graph1":"Peptide","graph2":"OrthoTrophix"},{"orgOrder":0,"company":"Dyve Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dyve Biosciences Announces Phase 2 TARGETS Study of DYV702 for Pain Associated with Acute Gout Flares Showcased in Podium Presentation at 2022 EULAR Congress","therapeuticArea":"Rheumatology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Dyve Biosciences"},{"orgOrder":0,"company":"LG Chem","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LG Chem Enters Final Stage of Clinical Development for New Gout Drug","therapeuticArea":"Rheumatology","highestDevelopmentStatus":"Phase II","country":"SOUTH KOREA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"LG Chem"},{"orgOrder":0,"company":"Jiangsu Atom Bioscience & Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Atom Bioscience to Present Final Data from its Positive Phase 2a Clinical Trial in Chronic Gout at American College of Rheumatology Annual Meeting, Nov. 10 \u2013 14, in Philadelphia, PA","therapeuticArea":"Rheumatology","highestDevelopmentStatus":"Phase II","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Jiangsu Atom Bioscience & Pharmaceutical"},{"orgOrder":0,"company":"Jiangsu Atom Bioscience & Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Atom Bioscience Announces Positive Results of Phase 2a China Clinical Trial of Its URAT1 Inhibitor for Chronic Gout","therapeuticArea":"Rheumatology","highestDevelopmentStatus":"Phase II","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Jiangsu Atom Bioscience & Pharmaceutical"},{"orgOrder":0,"company":"Arthrosi Therapeutics","sponsor":"Guangrun Health Industry","pharmaFlowCategory":"D","amount":"$75.0 million","upfrontCash":"Undisclosed","newsHeadline":"Arthrosi Secures $75M in Series D Financing","therapeuticArea":"Rheumatology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Arthrosi Therapeutics"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Product Type
          filter News Type

            Active Filter(s):

            Product Type

            Companies

            Details:

            The company intends to use the net proceeds to fund the development of AR882, a highly potent and selective next-gen URAT1 inhibitor delivered in a once daily immediate release oral capsule, being developed for the treatment of gout.

            Lead Product(s): AR882

            Therapeutic Area: Rheumatology Product Name: AR882

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Guangrun Health Industry

            Deal Size: $75.0 million Upfront Cash: Undisclosed

            Deal Type: Series D Financing July 12, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            ABP-671 is a small molecule inhibitor of the urate transporter 1 (URAT1) protein, which is involved in the reabsorption of uric acid by the kidneys. In gout patients, ABP-671 reduces the reabsorption of uric acid, increasing its excretion in urine.

            Lead Product(s): ABP-671

            Therapeutic Area: Rheumatology Product Name: ABP-671

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 01, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            ABP-671 was well tolerated, with the overall incidence of treatment emergent adverse events similar between the ABP-671 treatment cohorts and the placebo cohorts.

            Lead Product(s): ABP-671

            Therapeutic Area: Rheumatology Product Name: ABP-671

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 10, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Results from US Phase 2 clinical trial—primary end point set at a challenging level confirmed the potential of LC350189 (tigulixostat) as a new gout treatment distinguished from pre-existing drugs, while also demonstrating safety similar to that of the placebo group.

            Lead Product(s): Tigulixostat

            Therapeutic Area: Rheumatology Product Name: LC350189

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable August 03, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Topical application of DYV702 significantly reduced pain intensity and duration of acute gout flare with higher overall response rates, faster time to resolution, improvements in physical function and reduction in rescue medication use.

            Lead Product(s): DYV702,Colchicine

            Therapeutic Area: Rheumatology Product Name: DYV702

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable June 01, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The presentation demonstrated clinically meaningful improvement of TPX-100 in overall knee pain and in specific key pain parameters in moderate to severe knee OA, linked to significant reductions in pathological bone shape change.

            Lead Product(s): TPX-100

            Therapeutic Area: Rheumatology Product Name: TPX-100

            Highest Development Status: Phase II Product Type: Peptide

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable April 08, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Preliminary data suggest Atom’s compound ABP-671, a small molecule inhibitor of the urate transporter (URAT1) protein reduces uric acid levels to prevent gout flare-ups without the adverse side effects of existing treatments.

            Lead Product(s): ABP-671

            Therapeutic Area: Rheumatology Product Name: ABP-671

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 21, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Funding will support company’s anticipated global Phase III clinical trial of lead product, ABP-671, for treatment of hyperuricemia and gout, which affects more than 255 million people worldwide.

            Lead Product(s): ABP-671

            Therapeutic Area: Rheumatology Product Name: ABP-671

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Xicheng Jinrui Equity Investment Fund

            Deal Size: $45.0 million Upfront Cash: Undisclosed

            Deal Type: Series C Financing January 05, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY